Summary: A large meta-analysis has found no link between hormonal contraception and idiopathic intracranial hypertension (IIH). IIH is a potentially serious neurological disorder marked by elevated pressure in the cerebrospinal fluid surrounding the brain; it can cause chronic headaches, visual disturbances, and in rare cases permanent vision loss.
Because IIH most often affects women of reproductive age, questions have persisted about whether hormonal contraceptives—such as birth control pills, intrauterine devices (IUDs), implants, injections, rings, or patches—might trigger or worsen the condition. After pooling data from more than 674,000 women, researchers conclude that hormonal contraception is not associated with an increased prevalence of this brain pressure disorder.
Key Facts
- Study scope: The meta-analysis combined results from 13 studies that included 5,351 women diagnosed with IIH and a control group of 669,260 women without the condition. The average participant age across studies was about 33 years.
- All delivery methods examined: No increased prevalence of IIH was observed across a range of hormonal contraceptive methods, including oral contraceptive pills, IUDs that release hormones, contraceptive vaginal rings, injectable methods such as medroxyprogesterone, subdermal implants, and transdermal patches.
- Who is affected: IIH is most commonly diagnosed in women in their 20s to 40s. Obesity remains the strongest established risk factor for IIH.
- Clinical implications: The findings address and help correct inconsistent clinical advice that has, at times, recommended against hormonal contraception for people with or at risk for IIH based on theoretical concerns.
Source: AAN
Hormonal contraception, including birth control pills and intrauterine devices, is not associated with an increased prevalence of idiopathic intracranial hypertension, according to a meta-analysis published March 25, 2026, in Neurology.
Idiopathic intracranial hypertension occurs when cerebrospinal fluid pressure around the brain rises without an identifiable cause. Symptoms can include severe or chronic headaches and visual problems, and if untreated or severe, IIH can lead to permanent vision loss. While the precise cause of IIH is not fully understood, excess body weight is the most consistently identified risk factor. Because most diagnosed patients are women of reproductive age, clinicians and patients have long wondered whether exposure to sex hormones via contraceptives could influence disease risk.
“Health advice for people living with idiopathic intracranial hypertension is inconsistent due to a concern that hormonal contraception, including birth control pills and IUDs, may be associated with a higher risk of the condition in certain individuals,” said study author Arun N. E. Sundaram, MD, FRCPC, of the University of Toronto. “However, our meta-analysis found no association between hormonal contraception and idiopathic intracranial hypertension prevalence.”
The included studies examined a variety of hormonal methods, and no specific delivery system was linked to a higher prevalence of IIH. This broad review therefore provides more comprehensive evidence than single-study reports and helps clarify a clinical question that has generated mixed recommendations.
The authors emphasize that while these findings are reassuring for people considering or using hormonal contraception, the available evidence has limitations. Only 13 studies met inclusion criteria for the meta-analysis, and several of those had relatively small sample sizes. Small studies reduce the precision of estimates and may miss subtle associations that larger, more diverse studies could detect.
Given these limitations, the researchers call for larger, well-designed prospective studies that include diverse patient populations and detailed information about the timing and duration of contraceptive use. Such research would strengthen confidence in guidance for patients and clinicians who must balance the benefits and risks of contraceptive options, particularly for people with existing IIH or other risk factors.
In the meantime, this meta-analysis supports counseling that hormonal contraception does not appear to increase the prevalence of IIH. For individuals with IIH or concerns about elevated intracranial pressure, care decisions should remain individualized—taking into account each person’s medical history, weight management strategies, visual symptoms, and contraceptive needs—while clinicians remain attentive to emerging evidence.
Key Questions Answered:
A: IIH is a condition in which cerebrospinal fluid pressure around the brain is abnormally high without an identifiable cause; because its symptoms can resemble those of a brain tumor, it is sometimes called pseudotumor cerebri.
A: The near-exclusive occurrence of IIH in women during their reproductive years led clinicians to hypothesize a hormonal role, prompting caution in some clinical recommendations despite limited direct evidence.
A: The exact cause of IIH remains unknown, but obesity is the strongest established risk factor. Ruling out hormonal contraception as a likely major trigger allows patients and clinicians to focus on evidence-based management such as weight management and medical therapies to lower intracranial pressure.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff to clarify clinical relevance and study limitations.
About this neurology research news
Author: Natalie Conrad
Source: AAN
Contact: Natalie Conrad – AAN
Image: The image is credited to Neuroscience News
Original Research: The findings will appear in Neurology.